Ubrigene
Latest round
- Series C
Last raised
- Apr 2023
Total raised
- $71M
Investors
- 19
About Ubrigene
Established in 2015 and based in Beijing, China, Ubrigene is a biotechnology company that focuses on the development of advanced therapeutic drug technologies. It has GMP production bases in Maryland, Suzhou, Jinan, Guangzhou, Beijing and other places, and CMC global R&D centers in Vancouver and Nanjing. The chairman and CTO of the company, Xiulian Sun graduated from the University of British Columbia and has worked in WZ Biosciences Inc. In 2017, the company's first experimental cell drug entered the clinical stage. The company's business includes contract research organization (CRO) and contract development and manufacturing organization (CDMO) services for innovative cell and gene therapy drugs. It focuses on the development and production of clinical-grade viral vectors. Products include DNA (Deoxyribonucleic acid), RNA (Ribonucleic acid), virus, kits, and proteins. Ubrigene also provides analytical testing services. Products can be used to treat cancer, genetic diseases, and ophthalmic diseases. The company generates revenue by providing CRO, CDMO, and analytical testing services, and therapeutic drugs.
Who invested in Ubrigene
19 investors across 5 rounds
See all investors in Ubrigene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Ubrigene
Who invested in Ubrigene?
Ubrigene has 19 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Ubrigene raised?
Ubrigene has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Ubrigene last raise money?
Ubrigene's most recent round on record is a Series C, in Apr 2023.
What does Ubrigene do?
Established in 2015 and based in Beijing, China, Ubrigene is a biotechnology company that focuses on the development of advanced therapeutic drug technologies.
Where is Ubrigene headquartered?
Ubrigene is headquartered in Suzhou, China.
Which VCs invest in companies like Ubrigene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Ubrigene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Ubrigene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.